Autoimmune pediatric disorders
An evaluation designed specifically for children
This first-of-its-kind profile includes only the antibodies that are pertinent to pediatric CNS disorders — all in one evaluation. The antibodies included are supported by clinical research, and the results of this testing can help with diagnosis and long-term treatment planning.
MOG antibody is 11 times more common than AQP4 antibody in children
When to consider testing
Consider testing for children under 18 with suspected autoimmune encephalitis, or other autoimmune presentation such as ataxia or autoimmune encephalomyelitis, with one or more of the following:
Our pediatric autoimmune evaluation is part of an evolving approach to testing for autoimmune neurological disorders using phenotypic-specific evaluations that include multiple antibodies known for their disease association.
A Test in Focus
Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' pediatric autoimmune/CNS testing can better guide the treatment of autoimmune neurological diseases in children. The tailored evaluation covers only biomarkers relevant to pediatric presentations of the diseases.
This “Specialty Testing” webinar addresses the clinical presentations, evaluation (including diagnostic antibody testing), and treatment of autoimmune pediatric CNS disorders, including encephalitides and myelopathies.